Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

Phase 3

Conditions: Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Topotecan
Drug: Etoposide
Device: CT scans

First Posted Date: 2016-04-14

Last Posted Date: 2016-04-25

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 164

Registration Number: NCT02738346

Locations: 🇫🇷
Angers University Hospital, Angers, France

The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Apatinib
Drug: Etoposide

First Posted Date: 2016-04-11

Last Posted Date: 2016-04-12

Lead Sponsor: Third Military Medical University

Target Recruit Count: 25

Registration Number: NCT02733107

Locations: 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China

STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Etoposide
Drug: Hydroxychloroquine

First Posted Date: 2016-03-30

Last Posted Date: 2021-03-18

Lead Sponsor: University College, London

Target Recruit Count: 72

Registration Number: NCT02722369

Locations: 🇬🇧
UCLH, London, United Kingdom
🇬🇧
The Christie, Manchester, United Kingdom
🇬🇧
East and North Herts NHS Foundation Trust, Northwood, United Kingdom

and more 10 locations

PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma

Phase 2

Recruiting

Conditions: Treatment Refusal

Interventions: Drug: Gemcitabine
Drug: etoposide
Drug: Pegaspargase
Radiation: involved-field radiotherapy

First Posted Date: 2016-03-10

Last Posted Date: 2023-06-18

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 35

Registration Number: NCT02705508

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Please Select, China

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Phase 3

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Ibrutinib
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Vincristine
Drug: Idarubicin
Drug: Dexamethasone

First Posted Date: 2016-03-09

Last Posted Date: 2022-12-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 72

Registration Number: NCT02703272

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

Phase 1

Completed

Conditions: Hodgkin Disease

Interventions: Drug: Brentuximab Vedotin
Drug: Etoposide
Drug: Carboplatine
Drug: Ifosfamide

First Posted Date: 2016-02-19

Last Posted Date: 2021-12-07

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 53

Registration Number: NCT02686346

Locations: 🇧🇪
Clinique Universitaire Saint-Luc, Bruxelles, Belgium
🇧🇪
CHU Dinant Godinne, Yvoir, Belgium
🇫🇷
Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre, Caen, France

and more 16 locations